Introduction {#s1}
============

With mortality rates of liver cancer doubling in the last 20 years, this disease is on the rise and has become the fifth most common cancer in men and the seventh most common cancer in women.[@b1] Currently, hepatocellular carcinoma (HCC) represents approximately 90% of primary liver cancers and is a major global health concern.[@b2] There are many risk factors responsible for the development of HCC, such as viral infections, hereditary hemochromatosis, non-alcoholic fatty liver disease, increased alcohol-related liver disease, and cirrhosis, among others.[@b3] HCC development is a complex process involving multiple factors and pathways that lead to changes in gene expression, immune interactions, and changes in the tumor microenvironment that ultimately cause hepatocarcinogenesis.[@b4]

Screening for HCC in high-risk populations has become the standard of care, requiring imaging with ultrasound, computerized tomography, or magnetic resonance imaging every 6-12 months.[@b5] Laboratory tests, including mainly those for alpha feto-protein, the lectin Lens culinaris agglutinin-bound fraction of alpha feto-protein-3, and des-gamma-carboxy prothrombin, are used in conjunction with imaging to establish the diagnosis.[@b6],[@b7] Multiphasic imaging modalities, such as computerized tomography and magnetic resonance imaging, are used for detection and diagnosis of HCC. Liver biopsy is not necessary once the Liver Imaging Reporting and Data System (known as 'Li-Rads') has been deemed to be category 5, which is diagnostic for HCC.[@b8]

If a lesion is deemed to be HCC, the available options for management are varied and depend on multiple factors, including the number of lesions, their size, the presence of extrahepatic spread, and the severity of the patient's underlying liver disease.[@b9] The recommendation from The European Association for the Study of Liver panel of experts is to consider the following four related aspects to determine treatment options: tumor stage, degree of liver function impairment, general condition of the patient, and treatment efficacy.[@b10],[@b11] [Fig. 1](#f01){ref-type="fig"} depicts the Barcelona Clinic Liver Cancer system, which is one of the most commonly used algorithms to assist in determining treatment options based on the aforementioned factors.[@b11]--[@b14] To summarize, patients diagnosed as stage 0, with very early HCC, are ideal candidates for ablation or resection.[@b11] Patients who are deemed to be stage A, with early HCC, are candidates for radical therapies, including hepatoma resection, liver transplantation, or interventional radiology procedures.[@b10],[@b11] Patients at stage B, with intermediate HCC, may benefit from chemoembolization.[@b10],[@b11] Patients at stage C, who already have advanced HCC, are only candidates for systemic therapy if their performance status is acceptable; otherwise, they are managed with the best supportive care available.[@b11] Approximately 85% of patients with HCC are diagnosed at later stages or have underlying liver dysfunction, limiting their treatment options.[@b9] These patients usually have a very poor prognosis, with survival of less than 1 year.[@b15] In patients treated with resection or ablation, tumor recurrence (both true recurrence due to dissemination and *de novo* tumors) is unfortunately common and is seen in up to 70% of patients 3-5 years after treatment.[@b16]

![Hepatocellular carcinoma treatment in patients diagnosed with hepatocellular carcinoma.\
Modified Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy: The BCLC system recommends pathways for treatment based on prognostic stages. The stage is determined by the number of lesions and their size, evidence of extrahepatic spread/portal invasion, performance status (ps), preserved liver function, and evidence of decompensated liver disease (usually determined by the Child-Pugh classification or the model for end-stage liver disease score). As noted, there are multiple treatment options, including resection, transplantation, chemoembolization, ablation, systemic therapy or best support care, which is essentially palliative care. Survival is predicted based on what initial therapy was chosen.[@b11]](JCTH-8-168-g001){#f01}

Liver transplantation is an important treatment modality for patients who meet Milan criteria (a single HCC nodule of 2-5 cm or 3 HCC nodules each ≤3 cm in diameter) or who undergo down-staging of their tumors to be within the Milan criteria.[@b17]--[@b20] Studies have shown that patients who met Milan criteria and received a liver transplant had survival rates exceeding 70% at 5 years, with recurrence in less than 15% of patients.[@b21] Approximately 30-40% of patients on the liver transplantation waitlist are patients who have received model for end-stage liver disease (MELD) exception points for HCC.[@b22] They receive these points 6 months after listing and then receive an incremental increase in their MELD points every 3 months until the maximum MELD exception point allowance is reached (that being 34).[@b23],[@b24] MELD exception points give patients an increased chance of receiving a liver but they do not guarantee a liver to all listed patients. Therefore, additional treatments for HCC are greatly needed.

In 1891, the surgeon William Coley injected streptococcal organisms into a patient with inoperable osteosarcoma, successfully stimulating the immune system and leading to tumor regression and thus fathering the field of immunotherapy.[@b25] Since then, there have been many achievements in use of immunotherapy to fight cancer and in the development of a broad range of therapeutic applications, including the use of gene therapy, oncolytic viruses, cytokines, adoptive cell therapy, vaccines, and immune checkpoint inhibitors to fight cancer.[@b25]

Immunotherapy has recently become a new promising method for inhibiting HCC tumor progression, recurrence, and metastasis.[@b26],[@b27] "Immunotherapy" is a catch-all term, encompassing a wide range of applications and targets, including HCC vaccines, adoptive cell therapy (ACT), immune checkpoint inhibitors, and use of oncolytic viruses to treat HCC. These approaches have often shown initial success in treating other types of cancers, with potential to be similarly successful in treating HCC. In this review, we will discuss some of the most recent advancements in immunotherapy for HCC.

Tumor immunology {#s2}
================

Research has shown that cancer cells are able to escape from immunological surveillance and suppress the activation of immunocompetent cells (immune suppression), thereby allowing for their continued growth.[@b27] Cancer immunoediting is a proposed mechanism to explain how tumors evade the immune system, consisting of three sequential phases: elimination, equilibrium, and escape.[@b28] In the elimination phase, innate and adaptive immunity work together to destroy developing HCC long before it becomes clinically apparent. If this phase is not successful, the cancer cell variant may then enter the equilibrium phase, in which its growth is prevented by immunologic mechanisms.[@b28] Important players from the adaptive immune system, T cells, interleukin-12, and interferon-α suppress the growth of cancer cells during this phase.[@b28] The equilibrium state may represent an end stage of the cancer immunoediting process, creating occult cancers that do not grow any larger and are clinically insignificant during the lifetime of the host.[@b28] However, because of this constant immune selection pressure placed on "genetically unstable" tumor cells, new cell variants can become (1) unrecognizable to the adaptive immune system, due to antigen loss and defects in antigen processing or presentation, (2) insensitive to immune effector mechanisms, or (3) able to induce an immunosuppressive state within the tumor microenvironment.[@b28] These tumor cells may then enter the escape phase, in which their growth is no longer controlled by the immune system and clinically significant disease develops.[@b28]

An important escape mechanism allows tumor cells to up-regulate their own expression of immune checkpoint molecules, including the programmed cell death-1 (PD-1) protein that binds to the programmed death-ligand 1 (PD-L1) and stimulates peripheral T cell depletion.[@b29] Another important checkpoint molecule, cytotoxic T lymphocyte-associated protein 4 (CTLA-4), is found on the surface of T cells and can be activated by tumor cells, leading to down-regulation of T cells.[@b27] Interestingly, initial studies done by Duffy *et al.*[@b30] in 2017 showed that in liver biopsies of patients treated with tremeliomumab, an anti-CTLA-4 antibody, there was an increase in cytotoxic T cells, demonstrating that treatment with such molecules increased activity of the immune system. Monoclonal antibodies to PD-1, PD-L1, and CTLA-4 are called immune checkpoint inhibitors and have become an important part of immunotherapy treatments for many cancers, including melanoma, non-small cell lung cancer, and colorectal cancer, and are now emerging as valuable treatments in HCC.[@b29],[@b31]

Checkpoint inhibitors {#s3}
=====================

Checkpoint inhibitors are currently the most successful immunotherapy treatment for HCC.[@b27] As noted in [Tables 1](#t01){ref-type="table"} and [2](#t02){ref-type="table"}, and illustrated in [Fig. 2](#f02){ref-type="fig"}, there are multiple novel treatments available and many active clinical trials investigating further checkpoint inhibitors.

###### Results of selected studies testing immune checkpoint inhibitors in hepatocellular carcinoma. Adapted from Pinter and Peck-Radosavljevic.[@b25]

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial and year     Treatment (number of patients)          Target IT                  Prior sorafenib treatment, %   ORR/DCR, %   TTP/PFS in months   OS in months   Reference
  ------------------ --------------------------------------- -------------------------- ------------------------------ ------------ ------------------- -------------- -----------
  Sangro 2013        Tremelimumab (21)                       Anti-CTLA-4                23.8                           17.6/76.4    6.48/NR             8.2            49

  Duffy 2017         Tremelimumab + subtotal ablation (32)   Anti-CTLA-4                65.6                           26.3/NR      7.4/NR              12.3           30

  El-Khoueiry 2017   Nivolumab (80)                          Anti-PD-1                  0                              22.5/62.5    NR/NR               28.6           32

  El-Khoueiry 2017   Nivolumab (182)                         Anti-PD-1                  100                            18.7/62.6    NR/NR               15.6           32

  Wainberg 2017      Durvalumab (40)                         Anti-PD-L1                 92.5                           10/32.5      NR/2.7              13.2           73

  Kelley 2017        Durvalumab + tremelimumab (40)          Anti-PD-L1 + Anti-CTLA-4   75                             25/57.5      NR/NR               NR             74

  Zhu 2018           Pembrolizumab (104)                     Anti-PD-1                  100                            17.3/61.5    NR/4.9              12.9           37

  Ikeda 2018         Pembrolizumab + lenvatinib (30)         Anti-PD-1                  13.3                           42.3/100     NR/9.7              NR             42

  Stein 2018         Atezolizumab + bevacizumab (43)         Anti‐PD‐1 +\               0                              65/96%       NR/NR               NR             51
                                                             anti-VEGF                                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CTLA--4, cytotoxic T lymphocyte--associated protein 4; DCR, disease control rate; IT, immunotherapy; NR, not reported; ORR, overall response rate; OS, overall survival; PD--1, programmed cell death-1; PD--L1, programmed cell death 1-ligand 1; PFS, progression--free survival; TTP, time to progression.

###### Ongoing phase III trials testing immune checkpoint inhibitors in hepatocellular carcinoma

  Drug                                       Target of IT                  Setting                ClinicalTrials Identifier   Status                   Primary completion
  ------------------------------------------ ----------------------------- ---------------------- --------------------------- ------------------------ --------------------
  Nivolumab vs. placebo                      Anti‐PD‐1                     Curative adjuvant      [NCT03383458]{.ul}          Recruiting               Q1 2022
  Nivolumab + TACE                           Anti-PD-1                     Curative adjuvant      [NCT03143270]{.ul}          Recruiting               Q1 2019
  Nivolumab + TACE                           Anti-PD-1                     Curative, adjuvant     [NCT03572582]{.ul}          Recruiting               Q3 2022
  Nivolumab vs. sorafenib                    Anti‐PD‐1                     Palliative, 1st‐line   [NCT02576509]{.ul}          Recruiting               Q3 2017
  Durvalumab ± tremelimumab vs. sorafenib    Anti‐PD‐L1 + Anti‐CTLA‐4      Palliative, 1st‐line   [NCT03298451]{.ul}          Recruiting               Q1 2020
  Atezolizumab + bevacizumab vs. sorafenib   Anti‐PD‐L1                    Palliative, 1st‐line   [NCT03434379]{.ul}          Recruiting               Q2 2021
  Pembrolizumab vs. placebo                  Anti‐PD‐1                     Palliative, 2nd‐line   [NCT02702401]{.ul}          Active, not recruiting   Q1 2019
  Pembrolizumab + TACE                       Anti‐PD‐1                     Curative, 2nd‐line     [NCT03397654]{.ul}          Recruiting               Q4 2019
  Pembrolizumab vs. placebo                  Anti‐PD‐1                     Palliative, 2nd‐line   [NCT03062358]{.ul}          Recruiting               Q4 2019
  Pembrolizumab vs. best supportive care     Anti‐PD‐1                     Palliative, 2nd‐line   [NCT02702401]{.ul}          Active, not recruiting   Q4 2020
  Tislelizumab vs. sorafenib                 Anti‐PD‐1                     Curative, 1st‐line     [NCT03412773]{.ul}          Recruiting               Q4 2022
  Atezolizumab + bevacizumab                 Anti‐PD‐L1 + anti-VEGF        Curative, 1st‐line     [NCT03434379]{.ul}          Recruiting               Q2 2022
  Ipilimumab + nivolumab                     Anti-CTLA-4 + Anti‐PD‐1       Curative, adjuvant     [NCT03682276]{.ul}          Recruiting               Q4 2022
  Nivolumab + yttrium-90                     Anti-PD-1                     Curative, adjuvant     [NCT03033446]{.ul}          Recruiting               Q4 2019
  Pembrolizumab + talimogene laherparepvec   Anti-PD-1 + Oncolytic Viral   Curative, adjuvant     [NCT02509507]{.ul}          Recruiting               Q3 2021
  durvalumab + tremelimumab + radiotherapy   Anti-PD-L1 + Anti-CTLA-4      Curative, adjuvant     [NCT03482102]{.ul}          Recruiting               Q4 2025

Abbreviations: CTLA--4, cytotoxic T lymphocyte--associated protein 4; IT, immunotherapy; PD--1, programmed cell death-1; PD--L1, programmed cell death 1-ligand 1.

![Mechanism of action of checkpoint inhibitors under investigation for hepatocellular carcinoma treatment.\
Hepatocellular carcinoma (HCC) tumor cells can up-regulate expression of programmed cell death-1, PD-1, which binds the programmed death-ligand 1, PD-L1, and stimulates peripheral T cell depletion.[@b29] They can also activate cytotoxic T lymphocyte-associated protein-4 (CTLA-4), found on the surface of T cells and leading to down-regulation of T cells.[@b27] Ipilimumab and tremelimumab bind to and inactivate CTLA-4, preventing its activation. PD-1-PD-L1 binding may be prevented by therapeutically blocking either PD-1 (nivolumab, pembrolizumab, tislelizumab, and camrelizumab) or PD-L1 (durvalumab and atezolizumab).](JCTH-8-168-g002){#f02}

Nivolumab {#s3-1}
---------

Promising results were reported in 2017 from the Checkmate 040 phase I/II trial which looked into survival rates for nivolumab, an anti-PD-1 antibody, used in the treatment of advanced HCC.[@b32] A dose-escalation and expansion phase was implemented in patients who met strict inclusion criteria, with clinically less severe underlying liver dysfunction.[@b32] Treatment in 262 patients yielded an acceptable safety profile and promising efficacy, and based on these results, the Food and Drug Administration fast-tracked the approval of nivolumab for the treatment of patients diagnosed with HCC who had been previously treated with sorafenib.[@b27] Another small phase II trial investigating nivolumab alone versus nivolumab and ipilimumab is currently underway, with preliminary results demonstrating a good safety profile and that treatment does cause delay to surgical resection.[@b33]

Checkpoint 459 is a phase III study comparing nivolumab and sorafenib as first-line treatment for HCC.[@b34] Preliminary data was released in June 2019, which showed that the overall survival failed to meet statistical significance (hazard ratio of 0.85; 95% confidence interval, 0.72-1.02; *p*=0.0752). The data reportedly did show a trend towards an overall survival improvement with nivolumab versus sorafenib.[@b34] At the time of this publication, Bristol-Myers Squibb has not yet released the full data.[@b34] There are also currently other ongoing trials investigating nivolumab as a single agent in CheckMate-9DX and also in combination with ipilimumab for previously-treated patients with HCC.[@b26],[@b35],[@b36]

Pembrolizumab {#s3-2}
-------------

While nivolumab was investigated as a first-line treatment option for HCC, another anti-PD-1 antibody, pembrolizumab, is being developed as a second-line treatment after initial treatment with tyrosine kinase inhibitors have failed or were not tolerable.[@b27] In a phase II trial, patients with advanced liver cancer who were sorafenib-refractory, sorafenib-intolerant, or sorafenib-naïve received one standard dose of pembrolizumab.[@b37] Interval results showed an 18% response rate and a 12.9 month median survival period.[@b37] In November of 2018, the Food and Drug Administration granted an accelerated approval for pembrolizumab to be used in treatment of patients with HCC who have been previously treated with sorafenib.[@b37] However, in the follow-up, phase III KEYNOTE-240 trial, pembrolizumab failed to meet the primary endpoints for both overall survival and progression-free survival when pembrolizumab was compared to placebo and best supportive care in HCC patients that had already failed systemic therapy.[@b38] While pembrolizumab compared with placebo did show improvement in overall survival and progression-free survival, the improvement was not deemed statistically significant (overall survival:hazard ratio, 0.78; 95% confidence interval, 0.611-0.998; *p*=0.0238; progression-free survival:hazard ratio, 0.78; 95% confidence interval, 0.61-0.99; *p*=0.0219).[@b38] Although disappointing, this has not deterred other investigations of pembrolizumab in HCC patients. In the UK, a phase II/III study is underway investigating pembrolizumab as an adjunctive treatment to trans-arterial chemoembolization (TACE) using doxorubicin and gelatin sponges.[@b27]

An additional phase III study, KEYNOTE-394 (NCT03062358), is currently evaluating and recruiting patients and is using the same inclusion criteria as set in the Keynote-240 trial in hopes of better outcomes in an Asian population.[@b39]

Tislelizumab {#s3-3}
------------

Tislelizumab, another anti-PD-1 antibody, is currently under development by BeiGene.[@b40] The safety of tislelizumab was established in an earlier phase I trial, with multiple different solid cancers, including HCC.[@b41] Currently, there is a multicenter global phase III trial looking at tislelizumab versus sorafenib as first-line treatment for unreachable HCC that started recruitment in 2017.[@b27],[@b40],[@b42] This trial set survival rate as the principal endpoint and was designed to validate that non-inferiority of tislelizumab compared to sorafenib ([Table 2](#t02){ref-type="table"}). No interim data are currently available.

Camrelizumab {#s3-4}
------------

Camrelizumab is an anti-PD-1 antibody, for which a phase II/ III trial is currently underway in China, looking at patients who failed to respond to systemic treatments or were intolerant to previous systemic treatments.[@b27] Provisional results from the phase II part was presented in 2018 at a meeting of the European Society for Medical Oncology, demonstrated a response rate of 13.8% (30/217) with a 6-month overall survival rate of 74.7%.[@b27] It is notable that only two patients (0.9%) experienced grade 5 treatment-related adverse events, which in turn showed camrelizumab to have a suitable toxicity profile.[@b27] No interim date is available from the phase III part. Currently, there is an ongoing phase II trial in China looking at camrelizumab plus the FOLFOX4 regimen (consisting of 5-fluorouracil, leucovorin, and oxaliplatin) for treatment of advanced HCC and biliary tract cancers in patients who failed systemic treatment.[@b43] Interim results from October 2018 were promising, with median progression-free survival of 5.5 months; however, over 85% of patients had severe treatment related side-effects.[@b43]

Durvalumab {#s3-5}
----------

Durvalumab is the only anti-PD-L1 antibody for HCC under investigation currently.[@b27] Cancer cells can avoid immune surveillance by overexpressing PD-L1 and activating PD-L1/PD-1 signaling, which is observed in HCC tissues ([Fig. 2](#f02){ref-type="fig"}).[@b44],[@b45] A basic science study recently showed that inhibition of PD-L1 and DNA methyltransferase 1 (commonly known as DNMT1) significantly suppressed the growth of sorafenib-resistant HCC cells *in vitro.*[@b46],[@b47] This points to a possible novel treatment option for sorafenib-resistant HCC.[@b26],[@b48] A phase I/II trial looking at the safety of durvalumab monotherapy in treating solid tumors showed durvalumab to have an acceptable safety profile and to be promising, with a 10% response rate and a median survival time of 13.2 months for the HCC cohort.[@b26] A phase III trial that started in 2017 is currently underway looking at durvalumab plus tremelimumab combination therapy as a first-line treatment for patients with advanced HCC; however, currently there are no interim results available.[@b27]

Tremelimumab {#s3-6}
------------

Tremelimumab is another anti-CTLA-4 antibody under investigation for HCC.[@b27] To date, remelimumab monotherapy has been investigated for patients with HCC and chronic hepatitis C.[@b49] Results from the trial were promising, and showed that of the 21 patients enrolled, there was a partial response rate of 17.6% and a median time to progression of 6.48 months.[@b27] Overall, the treatment was very well tolerated, with minimal toxicities, such as transient elevation of transaminases, noted.[@b27] A phase I/II trial investigating the combination of tremelimumab plus interventional procedures, such as radiofrequency ablation, TACE, and cryoablation, for non-resettable HCC patients is currently underway in the USA.[@b30] Initial results show no dose limiting toxicities and of the 19 patients that were suitable for evaluation, 5 (26.3%) achieved partial responses outside of the areas treated with TACE or ablation.[@b27] The median progression-free survival period was 7.4 months, with the median survival period of 12.3 months.[@b25]

Combined targeted therapy {#s4}
=========================

Atezolizumab + bevacizumab {#s4-1}
--------------------------

Novel combination treatment with atezolizumab, an anti-PDL-1 antibody, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) therapy, is under investigation for treatment of advanced HCC and has shown to be effective in combination when treating other cancers.[@b50] HCC tumors over-express VEGF and PD-L1 and there is evidence of increased vascularity, which makes it a good target for this combination therapy that targets both sites.[@b51]--[@b53] Two global I/Ib studies showed promising results when looking at this combo in patients with unrespectable HCC who had not received prior systemic therapy but some of who received TACE and/or radiotherapy.[@b54] Data from the non-randomized arm of 119 patients showed an objective response rate of 36% (95% confidence interval, 26--46), with 12% of enrolled patients having complete response to treatment and a median overall survival of 17.1 months.[@b54]

The second arm of the study randomized the same patient population to atezolizumab and bevacizumab versus atezolizumab monotherapy.[@b54] Of those who received the combination therapy, 20% had confirmed responses and 47% had stable disease, compared to 17% and 32% of patients, respectively, in the atezolizumab monotherapy group.[@b54] This accounted for the 0.55 hazard ratio (80% confidence interval, 0.40--0.74; *p*=0.0108) reported.[@b54] Additionally, median progression-free survival in the combination arm was 5.6 months compared to 3.4 months in the monotherapy group.[@b55]

There were increased grade 3/4 adverse events in the combination group (34% vs. 14%) with the most common adverse events being proteinuria, fatigue, and rash.[@b54] Based on data that showed an objective response rate of 36% (95% confidence interval, 26--46), the Food and Drug Administration granted Breakthrough Therapy Designation for atezolizumab/bevacizumab combination therapy to be a fist-line therapy for advanced or metastatic HCC.[@b55] In addition, enrollment for a new phase III study, IMbrave150 (NCT03434379), has completed enrollment and will be comparing atezolizumab/bevacizuma versus sorafenib in unresectable HCC patients.[@b55]

Ipilimumab + nivolumab {#s4-2}
----------------------

Ipilimumab is an anti-CTLA-4 antibody and multiple studies have recently investigated its use in combination with nivolumab. In the USA, the CheckMate040 trial results were recently published (NCT01658878).[@b56] The trial enrolled HCC patients who had failed treatment with sorafenib and randomized the patients to receive one of three different protocols of ipilimumab plus nivolumab. The combined treatment reportedly showed an acceptable safety profile, with an objective response rate that was twice that of nivolumab monotherapy (31% compared to 14%) and having median overall survival of 18 months.[@b56]

In the UK, the PRIME-HCC clinical trial is underway, assessing the efficacy of combination treatment pre-operatively with nivolumab and ipilimumab in HCC patients for whom liver resection is planned.[@b27] Participants will receive two doses of nivolumab and a single dose of ipilimumab in the weeks before their surgery. This is a single-arm, open-label study to be conducted in 32 patients at a small number of UK hospitals. The study has two parts. Part 1 will confirm, in a small number of patients, that the treatment regimen is safe and does not result in delay to liver resection, while Part 2 will expand the number of patients studied and assess survival over 2 years post-resection. The decision to proceed to Part 2 will be taken with advice from an independent, expert committee.[@b27]

SHR-1210 + Apatinib {#s4-3}
-------------------

The combination of SHR-1210, a novel anti-PD-1 antibody, and apatinib, a tyrosine kinase inhibitor selectively acting on VEGF receptor 2, is currently being investigated.[@b27] A phase 1 trial was completed in 2018 and showed acceptable tolerability of this combination and a response rate of 38.9%, with a median progression-free survival of 7.2 months for the 18 patients with HCC.[@b44] Overall, adverse events were relatively tolerable, with only one patient discontinuing the treatment due to treatment-related grade 3 hyperbilirubinemia.[@b44] Currently, a phase II trial is underway in the USA, comparing this combination to systemic chemotherapy in advanced HCC.[@b57] No results are available currently.

Other targets in immunotherapy {#s5}
==============================

ACT is a new approach to look for treatments that allow a patients' own lymphocytes to attack cancer cells.[@b58],[@b59] Adoptive immunotherapy for HCC includes cytokine-induced killer cells, tumor-infiltrating lymphocytes, natural killer cells, and chimeric antigen receptor (CAR) T cells. The safety of ACT in patients with HCC have been investigated in many preclinical studies, thus laying a foundation for its clinical applications.[@b58],[@b59]

CAR-T cell therapy, in particular, has been a very successful novel method of treating CD19-positive hematological malignancies, and its application has recently been considered in the treatment of solid tumors, including HCC.[@b33] Currently, there are no clinical trials investigating CAR-T cell therapy for HCC, as there have been many concerns about the drug causing cytokine-release syndrome, which affects up to 90% of patients and can cause cardiovascular, pulmonary, and central nervous system complications.[@b59]--[@b61] Additionally, there is currently a lack of specific tumor antigens to target in HCC, limited trafficking and penetration of CAR-T cells to tumor sites, and an immunosuppressive tumor microenvironment.[@b33] To overcome these difficulties, numerous strategies have been developed, including enhancing the selectivity of CARs and controlling CAR-T activity.[@b33] In a recent study by Guo *et al.*,[@b62] the investigators concluded that gene-edited CAR T cells with PD-1 deficiency have stronger antitumor activity than wild-type CAR T cells and future development of CAR T cells with modified gene-editing may help improve CAR T cell efficacy as a treatment for HCC.[@b62] In another basic research study, Li *et al.*[@b63] demonstrated that GPC3-targeting CAR T cells, in particular CAR.hYP7, are a promising therapeutic intervention for liver cancer that can be translated for human use.[@b63] There is hope that with further investigation and clinical trials, CAR-T cell therapy will become a viable option for HCC treatment.

Interferon monotherapy has also been explored as adjuvant therapy, to both prevent tumor recurrence as well as to inhibit development of HCC in patients with chronic hepatitis B and C infections.[@b64]--[@b66] According to a published report by Lai *et al.*,[@b67] interferon-α increased survival rates and encouraged tumor regression in patients diagnosed with advanced HCC. According to Obi *et al.*,[@b68] 16% of HCC patients with portal vein invasion who received a combination of 5-flurouracil and interferon-α treatment had complete response, while 36% had a partial response, as interferon-α can induce apoptosis and inhibit cell growth in HCC tumors.

Different than ACT, cell-mediated immunotherapy is a novel approach that has been used to exploit the unique pattern of proteins that are expressed specifically on tumor cells as targets. Tumor-targeted antibodies are mutant or aberrantly expressed antigens on the surface on cancer cells and can be potential targets of the adaptive human immune system.[@b36] Tumor-targeted antibodies are being investigated for HCC immunotherapy, with a focus on alpha feto-protein-directed treatments.[@b69] Another approach is to use oncolytic viruses to attack HCC tumor cells.[@b70]--[@b72] Theoretically, these viruses can selectively replicate in tumor cells and cause lysis without harming normal tissues.[@b26] Oncolytic virotherapy-mediated oncolysis not only leads to tumor regression but also provides important immune responses. Most investigations into oncolytic virotherapy are currently in the pre-clinical or early clinical stages but are promising.[@b70]

Conclusions {#s6}
===========

Immunotherapy is a promising new frontier for HCC treatment, with many novel new strategies currently under development. The incidence of HCC is rapidly increasing, and it is a major cause of morbidity and mortality both nationally and internationally. Though HCC can be a devastating disease, the best hope for prolonged survival is early screening and diagnosis. Although there is some debate regarding the ideal methods of surveillance, ultrasound with and without alpha feto-protein every 6-12 months is generally accepted as standard practice in the proper patient population. Currently, multiple therapeutic modalities are available and research investigating innovative options is ongoing. Most patients are best served in liver transplant centers, where a multidisciplinary approach can take place under the guidance of experienced transplant hepatologists and gastroenterologists. Advances in HCC prevention, detection, and treatments have resulted in improved survival for a disease that was, until recently, considered terminal. Randomized phase I-III trials of nivolumab, atezolizumab, durvalumab, ipilimumab and tislelizumab as monotherapy or combination therapy are currently being conducted. However, there is still much to be revealed regarding checkpoint inhibitors as well as immunotherapy involving gut microbiota and monocytes in the peripheral blood, so clinical trials are necessary to determine their full benefit. Immunotherapy and targeted molecular therapies have personalized medical therapy, while improving patient care, and hopefully future research can continue this endeavor.
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